A big scientific trial discovered {that a} day by day semaglutide tablet produced important weight reduction and well being advantages similar to injectable variations, setting the stage for doable FDA approval later this 12 months.
A day by day tablet containing semaglutide, the lively ingredient in Ozempic, helped adults with obese or weight problems lose considerably extra weight than placebo over 64 weeks, in keeping with outcomes printed at this time in The New England Journal of Drugs. The section 3 examine, OASIS-4, positions an oral model of Ozempic as a possible needle-free possibility for continual weight administration, pending U.S. regulatory evaluate.
Carried out at 22 websites in 4 international locations, OASIS-4 randomly assigned 307 adults with out diabetes in a 2:1 ratio to obtain oral semaglutide 25 mg (n=205) or placebo (n=102), alongside way of life counseling. The trial included a 12-week dose escalation and a seven-week off-treatment follow-up, spanning 71 weeks in whole with 64 weeks on remedy. Members had a body-mass index of no less than 30, or no less than 27 with no less than one weight-related complication.
The investigators report two complementary estimates of impact. Below the “trial product estimand,” which displays outcomes if all contributors adhered to therapy as supposed, individuals taking the semaglutide tablet misplaced a median of 16.6% of their baseline physique weight at week 64, in contrast with 2.7% on placebo. Greater than a 3rd (34.4%) within the oral semaglutide group achieved no less than 20% weight reduction, versus 2.9% with placebo. Utilizing the extra pragmatic “therapy coverage estimand,” which counts outcomes no matter excellent adherence, imply weight reduction was 13.6% with the tablet versus 2.2% with placebo, and 29.7% versus 3.3% achieved no less than 20% weight reduction.
Throughout analyses, contributors on the tablet had been considerably extra more likely to hit 5%, 10%, 15%, and 20% weight-loss thresholds than these on placebo (all P<0.001). Bodily perform, measured by the IWQOL-Lite-CT instrument, additionally improved meaningfully with the tablet, as did a number of cardiovascular danger components.
Trade Perspective
“The oral semaglutide 25 mg knowledge present compelling efficacy for an oral weight administration treatment with 16.6% weight reduction and a security and tolerability profile in line with injectable Wegovy,” stated Martin Holst Lange, chief scientific officer and govt vice chairman of Analysis & Improvement at Novo Nordisk. “At the moment, lower than 2% of people with weight problems within the US obtain weight problems treatment and Wegovy in a tablet might also tackle affected person choice for oral therapy. Pending FDA approval, ample provide can be accessible to satisfy the anticipated US demand as we hope to set a brand new therapy benchmark for oral weight reduction medicines for individuals with obese or weight problems.”
Though Ozempic is the model used for semaglutide in sort 2 diabetes and Wegovy is the model for continual weight administration, the corporate and outdoors specialists have often in contrast efficacy throughout the assorted semaglutide formulations. In OASIS-4, Novo Nordisk notes that oral outcomes had been comparable in magnitude to these reported beforehand for the injectable formulation.
Gastrointestinal unwanted side effects—well-known for the GLP-1 class—had been probably the most frequent opposed occasions and had been usually gentle to average and transient. Nausea occurred in 46.6% of these on the tablet versus 18.6% on placebo; vomiting occurred in 30.9% versus 5.9%, respectively. Hostile occasions resulting in discontinuation occurred in 6.9% on the tablet and 5.9% on placebo. Critical opposed occasions had been reported in 3.9% and eight.8%, respectively. Investigators stated the general tolerability profile aligns with that seen for injectable semaglutide throughout in depth post-marketing expertise.
Medical Implications
“The OASIS 4 trial outcomes additional underscore the numerous influence that semaglutide can have in attaining sustainable weight reduction and broader well being advantages,” stated Sean Wharton, MD, the examine’s lead writer and medical director of the Wharton Medical Clinic. “Oral semaglutide 25 mg builds on the confirmed efficacy and established security and tolerability profile of semaglutide and represents a big development in weight problems therapy. Individuals with obese or weight problems have particular person preferences, and with oral semaglutide as a possible new therapy possibility, extra of those that usually are not on therapy at this time might take into account beginning GLP-1 therapy.”
Novo Nordisk submitted a New Drug Utility to the U.S. Meals and Drug Administration in February 2025 for the once-daily oral semaglutide 25 mg as a remedy for continual weight administration—the primary oral GLP-1 to be filed for this indication in the US. The corporate says the FDA evaluate is anticipated to conclude by the tip of this 12 months. If accredited, manufacturing of the tablet for weight administration can be absolutely U.S.-based, with manufacturing already underway.
Consultants warning that OASIS-4 excluded individuals with diabetes, so the findings might not generalize to all sufferers who would possibly use semaglutide. The examine’s on-treatment period was 64 weeks; longer follow-up will assist make clear weight-loss upkeep and long-term cardiometabolic outcomes after dose stabilization or discontinuation.
Reference: “Oral Semaglutide at a Dose of 25 mg in Adults with Chubby or Weight problems” by Sean Wharton, Ildiko Lingvay, Pawel Bogdanski, Ruben Duque do Vale, Stephan Jacob, Tobias Karlsson, Chaithra Shaji, Domenica Rubino and W. Timothy Garvey, 17 September 2025, New England Journal of Drugs.
DOI: 10.1056/NEJMoa2500969
By no means miss a breakthrough: Join the SciTechDaily newsletter.
